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Abstract
Purpose We investigated the feasibility and acceptance of
electronic monitoring of symptoms and syndromes in onco-
logical outpatient clinics using a PALM (handheld computer).
Methods The assessment of a combination of symptoms and
clinical benefit parameters grouped in four pairs was tested in
a pilot phase in advanced cancer patients. Based on these
experiences, the software E-MOSAIC was developed,
consisting of patient-reported symptoms and nutritional intake
and objective assessments (weight, weight loss, performance
status and medication for pain, fatigue, and cachexia). E-
MOSAIC was then tested in four Swiss oncology centers. In
order to compare the methods, patients completed the E-
MOSAIC as a paper and a PALM version. Preferences of
version and completion times were collected. Assessments
were compared using Wilcoxon signed-rank tests , and the
test-retest reliability was evaluated.
Results The pilot phase was completed by 22 patients. Most
patients and physicians perceived the assessment as
useful. Sixty-two patients participated in the feasibility
study. Twelve patients reported problems (understand-
ing, optical, tactile), and five patients could not com-
plete the assessment. The median time to complete the
PALM-based assessment was 3 min. Forty-nine percent
of patients preferred the PALM, 23 % preferred a paper
version, and 28 % of patients had no preference. Paper
vs. PALM revealed no significant differences in symp-
toms, but in nutritional intake (p=0.013). Test-retest
(1 h, n=20) reliability was satisfactory (r=073–98).
Conclusion Electronic symptom and clinical benefit
monitoring is feasible in oncology outpatient clinics
and perceived as useful by patients, oncology nurses,
and oncologists. E-MOSAIC is tested in a prospective
randomized trial.
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Introduction
Patients with advanced, incurable cancer suffer from a variety
of symptoms such as pain, depression, or appetite loss. These
physical or psychological symptoms as well as nutritional
problems are often underestimated due to poor detection in
daily practice [22]. Furthermore, oncologists’ perceptions of
patients’ symptoms often differ from patient-reported experi-
ences [15]. An important focus of treatment in this patient
population is to achieve an improvement in health-related
quality of life (HRQL) [26]. Medical oncologists considered
HRQL as the most important outcome in assessing the effect
of palliative chemotherapy [16]. However, physicians’ deci-
sions regarding modification of palliative chemotherapy after
a patient consultation were weakly associated with their con-
siderations of HRQL [11].
Due to time pressure in daily practice and the multitude of
possible assessment parameters, several investigators
attempted to facilitate assessment by using computer-assisted
technology. The first studies assessed whether the computer-
ized collection of HRQL data is possible and whether the
provision of these data to oncologists improved patient-
oncologist communication and symptom control [32].
Collection of symptoms or HRQL information of patients by
touch pad devices in the waiting room were found to be
feasible and useful to identify discrepancies of patients’ and
health care professionals’ symptom assessment [30]. In oncol-
ogy, there is increasing evidence that computerized assess-
ment is feasible, including patient-reported outcome parame-
ters covering Qol data [7, 10, 28] or symptoms [8, 24, 31].
A meta-analysis of studies in diverse clinical settings indi-
cated that computer-based assessment of patient-reported out-
comes is equivalent to paper-based assessment, but equiva-
lence needs to be confirmed when developing new tools [17].
Although existing studies emphasize the importance of
patient reported outcomes such as HRQL for improved symp-
tom assessment and communication, this information can only
insufficiently guide treatment decisions of oncologists in daily
practice [12]. The effect of systemic anticancer therapy is
commonly monitored by tumor response and toxicity assess-
ment, which are measured by gold standards (i.e., RECIST,
CTCAE). Furthermore, anticancer treatment in palliative in-
tention can alleviate cancer-related symptoms even in the
absence of a tumor size response [13] while in some patients,
the reduction of tumor size does not necessarily imply a
benefit for the patient [23]. Therefore, a combination of ob-
jective clinical measurements and patient-reported symptoms
is used to guide anticancer therapy in the non-curative setting,
which can be conceptualized as syndromes or clinical benefit
parameters. In pancreatic cancer for instance, the endpoint
clinical benefit response (a composite assessment of pain, pain
medication intake, performance status, and weight) has be-
come an outcome parameter to assess the impact of anticancer
therapy on tumor-related symptoms [3]. Close monitoring of
both, patient-reported symptoms and clinical benefit parame-
ters (as objective indicators of disease control), are therefore
helpful to guide treatment during anticancer treatment in
palliative intention, in addition to tumor response and toxicity
information. We hypothesized that the availability of simulta-
neously assessed patient-reported symptoms and clinical data
could improve patient care.
We developed a computer-based assessment tool covering
both common symptoms and clinical benefit parameters for
patients with advanced incurable, symptomatic cancer and
tested its feasibility and acceptance in the setting of daily
oncology outpatient clinics.
Methods
The development process and feasibility testing was per-
formed in three phases in order to allow continuous modifi-
cations between the steps. First, a paper-based pilot phase was
performed at a single institution. Based on this experience, a
pilot software called “E-MOSAIC” (electronic monitoring of
symptoms and syndromes associated with advanced cancer)
for a handheld computer (PALM) was developed and
pretested in two institutions. Second, a feasibility study with
the PALM was carried out in four centers. Third, a survey
among oncologists about barriers using a computerized as-
sessment system was performed.
Inclusion criteria of patients and physicians
Eligible patients had advanced incurable solid cancer of any
type and were about to be treated with an anticancer therapy
with an expected tumor response rate below 20% based on the
literature. Any weekly to biweekly or continuous antineoplas-
tic treatment schedule, which required weekly visits, were
allowed. Patients had to have symptomatic disease, defined
as any symptom score≥3/10 on the Edmonton Symptom
Assessment Scale (ESAS) [6]. Eligible oncologists were re-
quired to be experienced in medical oncology defined as
certified specialists or more than two years of training in
medical oncology, and all doctors had to be familiar with
communication skills, defined as completion of a basic com-
munication skills course or an equivalent training.
Phase 1: paper-based pilot and development of E-MOSAIC
In the first phase, the paper-based symptom assessment sys-
tem was used in daily oncology practice. Immediately, before
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each physician visit, the patient completed the ESAS on
paper on three consecutive visits. The completed ESAS
sheets were then handed out to the treating oncologists.
They were asked to acknowledge the ESAS during the
consultation and transfer the values onto the patient mon-
itoring sheet (PMS). The PMS contained the four pairs of
s ym p t om s a n d c l i n i c a l b e n e f i t p a r am e t e r s
(pain/analgesics, fatigue/Karnofsky performance status
(KPS), anorexia/weight loss, depression/antidepressants).
As an outcome, the compliance of patients with the paper
version was assessed. The experiences of involved physi-
cians were assessed using the following questions: (1)
Was the clarity of treatment goal improved by the ESAS
or not, and if yes, how?, (2) What adaptations in the
monitoring sheet would be necessary for improvement?,
(3) Whether they believed that the novel monitoring sys-
tem of symptoms improved patients’ quality of life or not,
and if yes, how?, (4) To estimate the impact on their usual
consultation time, and (5) To provide an overall judgment
of the feasibility of the intervention on daily oncology
practice.
Development of E-MOSAIC
A computer-based version of the assessment was developed
for a PALM within the study team, consisting of one to two
nurses per center and the main investigators (MDs: specialists
in palliative medicine, medical oncology, and information
technology). In order to minimize contamination, only one
oncologist per center was involved, mainly for supervision,
but with minimal involvement in the instrument development
process.
For refining purposes, the team decided to add symptoms
other than the ones assessed by ESAS and to add any medi-
cations used for symptoms and syndromes other than pain.
Various response formats (visual analog scales, numerical
scales, checklists) and different electronic solutions (PALM,
flat-PC, touch screen computers) were evaluated. The word-
ing of the questions and the visual appearance (screenshots)
was coordinated with the quality of life office of the Swiss
Group for Clinical Cancer Research (SAKK). The experi-
ences of using the first PALM version with a few patients
were collected and transferred by fax or email to the study
center. The proposals for refinement of the assessments were
reviewed weekly by the investigators, the nurses, and the IT
specialist. Those adaptations that seemed necessary were pri-
oritized. After significant changes, readjusted palm computers
were sent to the participating centers. The teams also sug-
gested how to adapt procedures in the outpatient setting to
facilitate the E-MOSAIC assessment in routine practice (pa-
tients, weight assessment by nurses not doctors, printer pro-
cedures). Based on these processes, we developed the PALM-
based E-MOSAIC assessment.
Final E-MOSAIC assessment tool
E-MOSAIC consisted of three elements, which were complet-
ed at every visit, element P by the patient and elements G and
M with assistance of the nurses or study personnel. A
screenshot of the E-MOSAIC pain assessment is displayed
in Fig 1.
Element P: visual analog scales (VAS) 1–10 of the
following:
(a) Nine frequent symptoms (pain, fatigue, drowsiness,
nausea, anxiety, depression, shortness of breath, loss of
appetite, overall well-being);
(b) Up to three optional symptoms (from a list of 20);
(c) Patients’ estimated nutritional intake;
Element G:
(a) Actual body weight and height;
(b) Actual Karnofsky performance status (KPS);
(c) Weight loss, body mass index calculated automatical-
ly, at baseline only;
ElementM: predefined, simplified list of concomitant med-
ications for the following:
(a) Pain (NSAIDS, Opioids [electronic algorithm to de-
liver the morphine equivalent daily dose]);
(b) Fatigue (erythropoietin, methylphenidate);
(c) Anorexia/cachexia (progestins, procinetics).
After completion of the PALM-based assessments the data
was transferred immediately from the docking station onto the
local computer. A longitudinal monitoring sheet (LoMoS) was
created electronically, printed in less than 30 s, and added on
top of the patients’ file notes. The LoMoS is displayed in
Fig 2. Physicians were required to have the file notes present
before examining the patients.
The LoMoS was structured as follows:
(a) VAS pain and pain medication (opioids calculated as
morphine-equivalent daily dose, other analgesics);
(b) VAS fatigue and KPS, medication for fatigue;
(c) VAS anorexia, weight change, interventions for
anorexia;
(d) Individual symptoms;
(e) Clinical benefit (combination of pain, pain medica-
tion, and weight).
All patients completed the paper and the PALM version of
the assessment and entered demographic information, includ-
ing prior experience with computers.
The final E-MOSAIC included three components: (1) a
handheld application running on a Palm, (2) a synchronization
software running on a Windows desktop PC to synchronize
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Fig 1 Examples of a visual
analog scale for pain. a Blank.
b Filled out by the patient
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E-MOSAIC: longitudinal electronic monitoring of symptoms and syndromes
associated with advanced cancer in patients treated with chemotherapy in
palliative intention.
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Fig 2 Longitudinal monitoring sheet (LoMoS)
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patient master data and to pull the gathered data (elements P,
G, and M) from the handheld device to save it on a data
storage on the desktop PC, and (3) a reporting software
running on a desktop PC to build and print the LoMoS.
The handheld application was developed in a C++ program
with the open source Palm OS software development kit
(Palm OS version 5.3) to run on Palm PDAs. The synchroni-
zation between the PDA and desktop PCs was achieved by a
HotSync conduit. This was again programmed in C++ with
the open source Palm conduit software development kit. The
LoMoS was generated as a PDF (portable document format)
file using a self-developed Python script and the Reportlab
Toolkit. The PDF file could be viewed on screen or printed.
Phase 2: feasibility study
Physicians’, nurses’ and patients’ preferences, experiences,
and perceived usefulness were assessed by a questionnaire,
which was developed by an interdisciplinary group of physi-
cians and nurses and tested for face validity. Time needed to
explain how to use the PALM-based assessment and time
needed to complete the assessment was measured.
The reliability of the PALM-based assessment was tested
by comparing paper and PALM-based assessment of symp-
toms usingWilcoxon signed-rank tests. For test-retest reliabil-
ity of the PALM-based assessment after one hour, Pearson
correlation coefficients were used in a convenience sample.
Patients who were not experiencing significant change of their
symptoms within the hour as judged by the nurse or oncolo-
gist were eligible.
No formal sample size estimation was performed, but in
order to have a representative sample, it was planned to accrue
at least 10 patients from at least two oncologists at each of five
or more SAKK centers (total ≥50 patients).
Phase 3: oncologists’ survey
To explore potential barriers for implementing a randomized
trial with E-MOSAIC, the core study team collected potential
topics by discussions. Randomly selected physicians (two
senior oncologists, two junior oncologists, two palliative care
physicians working in the oncology department) were asked
in a focus group the question of potential barriers for conduct
of a randomized trial with six consecutive weekly visits using
E-MOSAIC assessments compared to standard of care. In a
qualitative thematic analysis of the focus group’s field notes,
three main barriers relating to study, patients, and feasibility
were identified. Questions for the survey (see Appendix) were
prepared and grouped according to these three major topics.
The final version of the survey was mailed to oncologists of
different cancer centers in Switzerland. Multiple answers and
comments in free text were possible. The responses were
Table 1 Demographics of patients of the pilot phase
Patients (n=22)
Sex
Male 14 (64 %)
Female 8 (36 %)
Age (years), median (range) 62 (42–75)
Tumor types
Colorectal and anal 9 (41 %)
Pancreatic, bile duct 4 (18 %)
Upper GI 3 (14 %)
Head and neck 4 (18 %)
Other (prostate, sarcoma) 2 (9 %)
Chemotherapy
Continuous treatment (capecitabine, gefitinib) 6 (27 %)
Weekly treatment (gemcitabine, irinotecan,
carboplatin/paclitaxel, docetaxel)
13 (59 %)
Biweekly treatment (oxaliplatin, with 5-FU) 3 (14 %)
Survival (weeks), median (range), n=21 23 (3–106)
Pain at baseline (VAS), median (range), n=21 4 (0–8)
Pain syndromes
Incident 9 (41 %)
Neuropathic 3 (14 %)
Psychological distress 5 (23 %)
More than one of the three pain syndromes 4 (18 %)
Missing 2 (9 %)
Fatigue at baseline (VAS), median (range), n=21 6 (2–10)
Fatigue syndromes
Cognitive fatigue (delirium) 9 (41 %)
Emotional fatigue (depression) 6 (27 %)
Physical fatigue (asthenia) 19 (86 %)
More than one of the three fatigue syndromes 9 (41 %)
Anorexia at baseline (VAS), median (range) 5 (1–10)
Anorexia/cachexia syndromes
No anorexia and no cachexia 4 (18 %)
Primary anorexia (paraneoplastic) 15 (68 %)
Primary cachexia (paraneoplastic) 13 (59 %)
Secondary anorexia (symptoms affecting
nutritional intake)
6 (27 %)
Secondary cachexia (starvation) 4 (18 %)
Significant edema 3 (14 %)
Significant ascites or pleural effusion 4 (18 %)
Missing 1 (5 %)
Shortness of breath at baseline, (VAS), median
(range), n=21
1 (0–9)
Respiratory syndromes
Presence of hypoxemia, defined as <92 % at
rest, no O2
1 (5 %)
Obstruction requiring steroids 0 (0 %)
Cachexia with severe muscle loss 3 (14 %)
Pulmonary infection 0 (0 %)
Cardiac failure 0 (0 %)
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anonymised and analysed using descriptive statistics accord-
ing to the three main categories.
Ethical considerations
A protocol was written in accordance with the seven universal
requirements for ethical clinical research [14]. The study was
performed in accordance with the Declaration of Helsinki and
the guidelines of Good Clinical Practice. All parts of the study
were approved by the local ethics committee.
Results
Paper-based pilot
The pilot included 22 patients with various tumor types.
Demographic and clinical data are summarized in Table 1.
All patients completed all three required ESAS sheets. For all
but one patient, the physicians completed the patient monitor-
ing sheets. In 77 % of patients, the treating physicians per-
ceived the novel symptom monitoring as useful for the daily
oncology practice. The benefit of having a longitudinal and
quantitative overview of symptomswas mentioned as positive
aspect. In 95 % of the patients, oncologists reported an im-
proved communication with the use of PMS, with relatives in
85 %, with other oncologist in 75 %, with other health care
professionals in 80 %, and with referring physicians in 63 %.
In 95 % of the cases, the physicians perceived clarity of
goals of treatment as improved, with a specific focus on
symptom control. In 76 % of the cases, the impact of the
intervention on patients’ quality of life was perceived as
beneficial. The reasons were better control of overall symptom
load (81 %), pain (86 %), fatigue (61 %), weight loss (38 %),
or respiratory symptoms (38 %). A positive clinical impact of
the assessment was seen by the physicians for the symptoms
such as pain in 94%, fatigue in 70%, weight loss in 75%, and
respiratory problems in 33 % of the patients.
Eighty percent of the patients perceived the assessment as
useful. However, the necessity to complete the PMS by hand
was perceived as too time consuming for daily oncology
practice, the reason why an electronic solution was developed.
Table 2 Demographics of patients in the feasibility part
Patients (n=62)
Sex
Male 31 (50 %)
Female 31 (50 %)
Age (years), median (range) 63.5 (23–86)
Tumor types
Colorectal and anal 12 (19 %)
Pancreatic, bile duct 2 (3 %)
Lung cancer 4 (6 %)
NHL/Hodgkin/leukemia 16 (26 %)
Breast cancer 11 (18 %)
Other (prostate, sarcoma) 11 (18 %)
Not specified 6 (10 %)
Metastatic disease 48 (77 %)
Main symptomsa
Pain 16 (26 %)
Fatigue 31 (50 %)
Nausea 4 (6 %)
Anorexia 11 (18 %)
Anxiety 7 (11 %)
Depression 2 (3 %)
Shortness of breath 4 (6 %)
Dizziness 5 (8 %)
Dry mouth 8 (13 %)
Othersb 40 (65 %)
No symptoms 2 (3 %)
Not reported 2 (3 %)
a Choice of three symptoms (free text) most patients interviewed by
nurses
b Symptoms occurring in six or less patients (e.g., dysphagia, sweating)
Table 3 Patients’ results of the feasibility part
Patients (n=57)
Time needed to complete E-MOSAIC with PALM
Less than 2 min 17 (30 %)
Between 2 and 5 min 23 (40 %)
More than 5 min 17 (30 %)
Time needed to complete the symptom
assessment by papera
Less than 2 min 44 (77 %)
Between 2 and 5 min 6 (11 %)
More than 5 min 2 (4 %)
Difficulties with completion of E-MOSAIC
Optical problems 4 (7 %)
Tactile problems 2 (4 %)
Problems of understanding 6 (11 %)
Did not E-MOSAIC 5 (9 %)
Other unspecified 0 (0 %)
No difficulties reported 45 (79 %)
Preference for PALM or paper
Paper version 13 (23 %)
PALM version 28 (49 %)
No preferences 16 (28 %)
Experience with computerb n=28
Experience with computers 7 (25 %)
No experience with computers 9 (32 %)
Little experience with computers 12 (43 %)
a Including only main symptoms and estimation of nutritional intake
bQuestions asked only subgroup
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Feasibility study
The PALM-based E-MOSAIC assessment system was ex-
plored in 62 patients with various tumor types. All demo-
graphic and clinical variables are summarized in Table 2.
Fifty-two patients completed the symptom assessment on
paper, which included only the nine main symptoms and the
estimation of nutritional intake. The majority of patients re-
quired less than 2 min (n=44) to complete the questionnaire
with six patients requiring more than three, and two patients
more than 5 min.
The time needed by the nurses to explain the E-MOSAIC
PALM assessment to patients (n=59) was less than 2 min in
42 patients, more than 3 min in 12, and more than 5 min in 5
patients. Seventeen patients needed less than 2 min to
complete E-MOSAIC, 23 more than 3 min, and 17 more than
5 min (see Table 3).
Difficulties with completion of the E-MOSAIC assessment
were observed in 12 patients (19 %), of whom 4 patients had
optical, 6 understanding and 2 patients had tactile problems,
and 5 of 62 (8 %) patients did not complete the full E-
MOSAIC assessment.
Of the 57 evaluable patients, 13 (23 %) patients preferred
the paper-based assessment of main symptoms, and 28 (49 %)
patients preferred the PALM-based assessment, 16 (28 %)
patients had no preference. Nurses (n=10) did judge for each
patient which tool they preferred. For 58 patients, the nurses
preferred the PALM in 44 cases (76 %), in 13 cases (22 %)
they had no preferences, and in 1 case they preferred the paper
version (Table 4).
Wilcoxon signed-rank tests showed no significant differ-
ences of PALM vs. paper of 9 symptoms (p values: 7 symp-
toms 0.249–940, well-being 0.089, dyspnea 0.060). For nu-
tritional intake, a significant difference was found (p value
0.013). The median (0–100) was 26, SD 30 on paper vs. 34
SD 31 on palm. Test-retest (1 h, n=20) reliability of nine
symptoms and nutritional intake assessed by Pearson correla-
tion coefficients was in a satisfactory range (r=0.73–0.98).
Survey of oncologists
The questionnaire was mailed to 36 oncologists, of which 18
(50 %) replied. Twelve were male, the average age was
37 years, and the average work experience was 4 years.
Continuity of care, reservations against computer technology
or research in general were the main barriers. The specific
quantification of concerns is provided in Table 5. Specific
answers added in free text were: “Palliative care patients have
to fill in enough assessment forms already” and “I appreciate
if the nurses perform the study.”
Discussion
Electronic symptom and clinical benefit parameter monitoring
proved to be feasible and was perceived as useful for onco-
logical outpatient management in Switzerland. Patient and
health care professionals generally accepted E-MOSAIC by
PALM. The completion rate in a multicenter setting was high.
In accordance to these results, a range of studies demon-
strated the feasibility of self-assessments in patients with
advanced, incurable cancer for various symptom assessment
tools [15]. Velikova et al. compared touch screen question-
naires with paper questionnaires for collecting data on quality
of life in oncological inpatients and showed that 52 % of
patients preferred the touch screen to a paper version [29].
Dearney evaluated the acceptability of using handheld com-
puters for symptom assessment in patients receiving
Table 4 Health care professionals’ results of the feasibility part
Patients (n=60)
Time needed by nurses
to explain PALM E-MOSAIC
Less than 2 min 42 (70 %)
Between 2 and 5 min 12 (20 %)
More than 5 min 5 (8 %)
Missing 1 (2 %)
Time needed by nurses to complete dataa
Less than 2 min 56 (93 %)
Between 2 and 5 min 2 (3 %)
More than 5 min 2 (3 %)
Preference of nurses of PALM or paper
Paper version 1 (2 %)
PALM version 44 (73 %)
No preferences 13 (22 %)
Missing 2 (3 %)
a For example, weight, KPS, and medications
Table 5 Barriers in implementing a trial with E-MOSAIC
n
Patient related factors
I don’t see patients regularly on a weekly basis 12
I don’t see enough patients matching the inclusion criteria 8
I am taking turns with other oncologists in treating the patients 8
Study
I think inclusion in such a study is difficult due to procedural reasons 13
The benefit of such as study is not clear 2
I don’t see a role for computers in the treatment of patients 1
Feasibility
No time for additional tasks in clinic 2
I was involved in the tests and the printer did not work 1
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chemotherapy. Most patients (66 %) had little previous com-
puter experience, and 74% of patients stated that the symptom
information would help in self-care and symptom manage-
ment [21].
There is evidence that computer-based assessment is feasi-
ble over a long period and from home: in a Norwegian
randomized controlled trial, a computer-assisted interactive
tailored patient assessment tool was repeatedly used to mea-
sure symptoms up to one year [27]. In another study, patients
were invited to report symptoms on an online platform from
home. One hundred twenty-five patients who received che-
motherapy were invited, 105 participated and showed a high
compliance and satisfaction with the system [2]. A random-
ized controlled trial tested the effect of the electronic self-
report assessment cancer (ESRA-C) in 660 cancer patients at
two centers. The output from the ESRA-C was displayed to
the treatment team. The primary outcome was the likelihood
of discussion of symptoms and quality of life issues (SQLIs)
between clinicians and patients. When the SQLIs were rated
as problematic, they were more discussed during the visits,
and the output was perceived as useful by clinicians [4]. In a
large international study, 1,017 cancer patients with incurable
metastatic or locally advanced disease from 17 centers in eight
countries reported on pain, depression, and physical function
using a touch screen laptop computer. The entire assessment
was completed by over 90 % of the patients, some of them
with far advanced disease [18]. These results document the
general acceptance of computer assessment by patients in
various settings. In a recent publication, it was once more
highlighted that computer technology is a possibility to inte-
grate HRQL information into routine oncology [19].
Limitations of our study include the fact that our results
may be biased by a selective sample of patients who were
fitter or who had more computer experience; however, we
used a convenient sample without tracking patients with better
health status. In addition, results on acceptability might have
been biased by patients’ willingness to provide positive re-
sponses. The age of patients varied widely in our sample and
mirrors the general oncology outpatient population [19].
Because patients had to learn how to use the system and are
seen by the nursing staff before consultation with the physi-
cian, we decided to offer nursing support to complete the
assessments, which may have influenced the outcomes to-
wards better acceptance.
The electronic device in our study was a PALM. It was
chosen at the time because it could be handed out to
patients and they were able to complete the assessment
with assistance of nurses (e.g., weight) while waiting for
blood results and doctor examination. Meanwhile, this
device unfortunately went out of production. We did not
compare other electronic tools with bigger screens to the
PALM. Problems of understandability, visual, and tactile
problems need to be addressed, and assistance when
handling the device should be in place, especially when
developing computer-based assessment systems on small
devices for an aging and sick population. The quantifica-
tion of nutritional intake on a visual analog scale might
be less accurate on small devices. Velikova and Detmar
utilized large touch screens in the waiting room where
confidentially issues may arise and patients might be too
sick to stand up and reach the touch screens [12, 29].
Assessment instruments have the immanent potential to
facilitate but as well the danger to hamper routine care.
Gatekeeping or objections against computer technology from
health care professionals might be a challenge in
implementing such approaches: in a recent publication, only
one out of 17 clinicians allowed lung cancer patients to take
part in a computerized symptom assessment study because of
concerns about the burden it induces to vulnerable patients
[9]. However, current evidence suggests that symptom assess-
ments may increase communication, if the information is
displayed to patient and physician. (15) Gatekeeping can be
overcome, if clinicians become aware of the benefit of com-
puterized systems [1]. A device is only used if it is of any help
to the staff and accepted by patients. Involvement of users
(patients and health care providers) during the development
and testing for effectiveness is therefore essential [25].
Our work may help to increase the assessment of symp-
toms and clinical benefit parameters in daily practice [20]. The
pragmatic approach may support oncologists who typically
work with limited time resources to elicit and to quantify each
patient’s individual symptoms. Future research needs to also
ask the question if the provision of symptom and clinical
benefit data will have an impact on the work of oncologists
and on patient care.
Overall, the E-MOSAIC tool shows good acceptance and
sufficient test-retest reliability compared to a paper version.
Based on these results, it was used in SAKK 95/06, a large
phase III trial in three languages regions (German, French, and
Italian) in Switzerland [5].
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Appendix
Barriers questionnaire
Study
The study is unclear.
The study is too extensive.
I don’t believe in such a study.
My focus is on therapy not studies.
I don’t see benefit in non-therapy associated studies.
I don’t believe in nurse led studies.
Patients
I don’t want to bother patients.
I don’t treat such patients.
My patients are not able to fill in palm based assessments.
I don’t see patients on a weekly basis.
My patients are in other studies.
Feasibility
I do not want to address palliative care issues.
My patients do not suffer from symptoms.
I don’t see patients on a regularly basis.
I was involved in the tests, and it was too complicated.
I don’t believe that computers are helpful.
I have no time for additional tasks in clinic.
I was involved in the tests and the printer did not work.
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